Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma

Inclusion Criteria: * Histological detection confirmed CD19/CD22 postive lymphoma; * Recieved more than 2 lines of chemotherapy; * Not eligible for hematopoietic stem cell transplantation or relapsed after hematopoietic stem cell transplantation; * Life expectation for more than 3 months; * ECOG ≥ 2; * Adequate organ function: EF≥50%; normal ECG; CCR≥40ml/min; ALT and AST ≤ 3 × upper limitation of normal, T-BIL ≤ 2.0mg/dl; PT and APTT \< 2 × upper limitation of normal; SpO2 \> 92%; * CBC results: Hb ≥ 80g/L, ANC \> 1 × 10E9/L, Plt ≥ 50 × 10E9/L; * Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion; * With measurable disease; * Written informed consent could be acquired; Exclusion Criteria: * Immunosuppressive agents or steroids in recent 1 week before recruitment; * Uncontrolled infection; * HIV positive ; * Active HBV or HCV infection; * Women in pregnancy and lactation; * Refuse to conception control during treatment and 1 year after CAR-T infusion; * Uncured malignancies other than non-Hodgkin lymphoma; * Have participated similar trial for treating relapse/refractory non-Hodgkin lymphoma; * Inheritated immune deficiancy; * Severe heart disease.